Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Nonalcoholic Steatohepatitis (NASH)

In brief

This is a phase II study of of Leronlimab (PRO 140)-Humanized monoclonal antibody to CCR5 in patients with Nonalcoholic Steatohepatitis (NASH).

Key facts

Study ID

NCT04521114

Run by

CytoDyn, Inc.

People needed

87

Starts

2020-12-01

Expected to finish

2021-12-29

Last updated by the study team

2023-03-01

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Southern California Research Center — Coronado, California, United States
• Meridien Research — Maitland, Florida, United States
• Floridian Clinical Research — Miami Lakes, Florida, United States
• Sensible Healthcare, LLC — Ocoee, Florida, United States
• Center for Advanced Research & Education — Gainesville, Georgia, United States
• Care United Research LLC — Forney, Texas, United States
• American Research Corporation — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.